Celularity Faces Nasdaq Delisting Notice

Ticker: CELUW · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1752828

Sentiment: bearish

Topics: delisting, compliance, nasdaq

Related Tickers: CELU

TL;DR

Nasdaq's coming for CELU's listing, big trouble ahead.

AI Summary

Celularity Inc. received a notice of delisting or failure to satisfy continued listing rules from the Nasdaq Stock Market on October 18, 2024. The company is currently evaluating the notice and will determine the appropriate course of action to regain compliance with Nasdaq's listing standards.

Why It Matters

This notice indicates Celularity may be at risk of being removed from the Nasdaq exchange, which could significantly impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — The company has received a notice of delisting, indicating a significant risk of being removed from the Nasdaq exchange.

Key Players & Entities

FAQ

What specific listing rule(s) did Celularity Inc. fail to meet?

The filing states Celularity Inc. received a notice of delisting or failure to satisfy a continued listing rule or standard, but does not specify which particular rule(s) were violated.

What is the earliest event date reported in this filing?

The earliest event date reported is October 18, 2024.

What is Celularity Inc.'s former company name?

Celularity Inc.'s former company name was GX Acquisition Corp.

When did Celularity Inc. change its name from GX Acquisition Corp.?

The date of the name change from GX Acquisition Corp. was September 12, 2018.

What is Celularity Inc.'s IRS Employer Identification Number?

Celularity Inc.'s IRS Employer Identification Number is 831702591.

Filing Stats: 677 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-10-21 07:24:58

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELULARITY INC. Date: October 21, 2024 By: /s/ Robert J. Hariri Robert J. Hariri, M.D., Ph.D. Chairman and CEO

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing